Corrigendum: The RNA helicase DDX46 inhibits innate immunity by entrapping m

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. m6A modification-mediated lncRNA UNC5B-AS1 enhances HCC progression through miR-760/IL6 axis.Scientific reports · 2026
   Article
2. WTAP-mediated m6A regulation in digestive system cancers: from molecular mechanisms to therapeutic strategies.American journal of cancer research · 2025
   Review
3. Cell-type-specific need of Ddx3 and PACT for interferon induction by RNA viruses.Journal of virology · 2023
   Article
4. Knockdown of DDX46 inhibits trophoblast cell proliferation and migration through the PI3K/Akt/mTOR signaling pathway in preeclampsia.Open life sciences · 2020
   Article
5. Association of N6-methyladenosine with viruses and related diseases.Virology journal · 2019
   Review

Corrections and comments

• Erratum for
  The RNA helicase DDX46 inhibits innate immunity by entrapping m2017

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract